Protalix, SarcoMed Partner to Advance PRX-110 for Pulmonary Sarcoidosis

Protalix, SarcoMed Partner to Advance PRX-110 for Pulmonary Sarcoidosis

287065

Protalix, SarcoMed Partner to Advance PRX-110 for Pulmonary Sarcoidosis

Protalix Biotherapeutics and SarcoMed USA have entered into an exclusive worldwide license agreement to advance PRX-110 (alidornase alfa) as a treatment of pulmonary sarcoidosis and other respiratory diseases. “Most patients with pulmonary sarcoidosis do not show symptoms and do not realize they have the disease until it has progressed to later stages. Currently available treatment options vary significantly from patient to patient, and the treatments generally either control symptoms or improve the patient’s lung function,” Dror Bashan,…

You must be logged in to read/download the full post.